Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2010

Open Access 01-11-2010

Pre-exposure Prophylaxis State of the Science: Empirical Analogies for Research and Implementation

Authors: Sarit A. Golub, Don Operario, Pamina M. Gorbach

Published in: Current HIV/AIDS Reports | Issue 4/2010

Login to get access

Abstract

Pre-exposure prophylaxis (PrEP) has the potential to become a powerful biomedical approach to HIV prevention; however, its success depends on behavioral and social factors that may determine its appropriate use. This article is designed to facilitate interdisciplinary empirical analogies relevant to PrEP implementation, reviewing behavioral and social science findings that may provide lessons critical to the success of PrEP as a biomedical–behavioral prevention strategy. As we prepare for the dissemination of new biomedical approaches to HIV prevention, integrating the state of the science across disciplines may result in innovative strategies for implementation that can enhance their success.
Literature
1.
Paltiel AD, Freedberg KA, Scott CA, et al.: HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806–815.CrossRefPubMed
2.
Vissers DC, Voeten HA, Nagelkerke NJ, et al.: The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE 2008, 3:e2077.CrossRefPubMed
3.
CDC: HIV/AIDS Surveillance Report, 2004. Atlanta: US Department of Health and Human Services; 2005.
4.
Grant RM: Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010, 50(Suppl 3):S96–S101.CrossRefPubMed
5.
UNAIDS &AIDS Vaccine Advocacy Coalition. Good participatory practice: Guidelines for biomedical HIV prevention trials. Geneva, Switzerland: 2007.
6.
• Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008, 12:1235–1254. This review syntehsizes information from over 70 studies regarding predictors of LTBI adherence and intervention efficacy. LTBI provides a useful model for understanding determinants of PrEP as a long-term, daily prophylactic treatment.PubMed
7.
Newman PA, Duan N, Kakinami L, Roberts K: What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine 2008, 26:2528–2536.CrossRefPubMed
8.
Coly A, Gorbach PM: Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS 2008, 3:581–586.CrossRefPubMed
9.
Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W: Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci 2009, In press.
10.
•• Visschers VH, Meertens RM, Passchier WW, de Vries NN: Probability information in risk communication: a review of the research literature. Risk Anal 2009, 29:267–287. This article provides an excellent meta-analysis as well as detailed, specific recommendations for communication about probability and risk to patients.CrossRefPubMed
11.
Reyna VF, Nelson WL, Han PK, Dieckmann NF: How numeracy influences risk comprehension and medical decision making. Psychol Bull 2009, 135:943–973.CrossRefPubMed
12.
13.
Chaiken S, Maheswaran D: Heuristic processing can bias systematic processing: effects of source credibility, argument ambiguity, and task importance on attitude judgment. J Pers Soc Psychol 1994, 66:460–473.CrossRefPubMed
14.
Kahneman D, Tversky A: Prospect theory: An analysis of decisions under risk. Econometrica 1979, 47:263–291.CrossRef
15.
Tversky A, Kahneman D: The framing of decisions and the psychology of choice. Science 1981, 211:453–458.CrossRefPubMed
16.
Edwards A, Elwyn G, Covey J, et al.: Presenting risk information—a review of the effects of “framing” and other manipulations on patient outcomes. J Health Commun 2001, 6:61–82.CrossRefPubMed
17.
• Mahajan AP, Sayles JN, Patel VA, et al.: Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS 2008, 22(Suppl 2):S67–S79. This article presents an important review of the scientific literature on HIV/AIDS stigma and explores critical challenges to future research, but also provides recommendations for the next steps in responding to stigma in the context of the HIV/AIDS epidemic.CrossRefPubMed
18.
Young SD, Nussbaum AD, Monin B: Potential moral stigma and reactions to sexually transmitted diseases: evidence for a disjunction fallacy. Pers Soc Psychol Bull 2007, 33:789–799.CrossRefPubMed
19.
Weinstock H, Dale M, Linley L, Gwinn M: Unrecognized HIV infection among patients attending sexually transmitted disease clinics. Am J Public Health 2002, 92:280–283.CrossRefPubMed
20.
Newman PA, Roungprakhon S, Tepjan S, Yim S: Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010, 28:958–964.CrossRefPubMed
21.
Young SD, Monin B, Owens D: Opt-out testing for stigmatized diseases: a social psychological approach to understanding the potential effect of recommendations for routine HIV testing. Health Psychol 2009, 28:675–681.CrossRefPubMed
22.
Simoni JM, Amico KR, Smith L, Nelson K: Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep 2010, 7:44–51.CrossRefPubMed
23.
24.
Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560–1571.CrossRefPubMed
25.
Okwundu C, Okoromah C: Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2009, 1.
26.
Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27.CrossRefPubMed
27.
Rosenberg MJ, Waugh MS, Meehan TE: Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995, 51:283–288.CrossRefPubMed
28.
Ingersoll KS, Cohen J: The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008, 31:213–224.CrossRefPubMed
29.
30.
•• Stirratt MJ, Gordon CM: Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep 2008, 5:186–192. This article provides insightful perspectives on the areas in which existing HIV adherence literature can inform research on biomedical prevention strategies.CrossRefPubMed
31.
Ware NC, Wyatt MA, Tugenberg T: Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care 2006, 18:904–910.CrossRefPubMed
32.
Padian NS, Buve A, Balkus J, et al.: Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008, 372:585–599.CrossRefPubMed
33.
Eaton LA, Kalichman S: Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007, 4:165–172.CrossRefPubMed
34.
Sood N, Goldman D: HIV breakthroughs and risky sexual behavior. Q J Econ 2006, 121:1063–1102.CrossRef
35.
Desai K, Sansom SL, Ackers ML, et al.: Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829–1839.CrossRefPubMed
36.
Wetmore CM, Manhart LE, Wasserheit JN: Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev 2010, In press.
37.
Rotheram-Borus M, Swendeman D, Chovnick G: The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Ann Rev Clin Psychol 2009, 5:143–167.CrossRef
38.
Burton J, Darbes LA, Operario D: Couples-focused behavioral interventions for prevention of HIV: systematic review of the state of evidence. AIDS Behav 2010, 14:1–10.CrossRefPubMed
39.
•• Munro S, Lewin S, Swart T, Volmink J: A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health 2007, 7:104. This paper provides one of the most comprehensive reviews and analysis of behavioral change theories and the evidence for their effectiveness in predicting and affecting behavior change.CrossRefPubMed
40.
Crepaz N, Hart TA, Marks G: Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004, 292:224–236.CrossRefPubMed
41.
Kalichman SC, Cherry C, Amaral CM, et al.: Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS 2010, 24:271–277.CrossRefPubMed
42.
Golub SA, Kowalczyk WJ, Weinberger CL, Parsons JT: Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010, In press.
43.
• Reyna VF: A theory of medical decision making and health: Fuzzy trace theory. Med Decis Making 2008, 28:850–865. This article discusses the application of Fuzzy Trace Theory to health and medical decision-making. It provides a novel approach to understanding risk perception and behavior, and applies existing data to the development of theory-based intervention strategies.CrossRefPubMed
44.
Reyna VF: How people make decisions that involve risk: A dual process approach. Curr Dir Psychol Sci 2004, 13:60–66.CrossRef
45.
46.
Metcalfe J, Mischel W: A hot/cool-system analysis of delay of gratification: dynamics of willpower. Psychol Rev 1999, 106:3–19.CrossRefPubMed
47.
•• Gutnik LA, Hakimzada AF, Yoskowitz NA, Patel VL: The role of emotion in decision-making: a cognitive neuroeconomic approach towards understanding sexual risk behavior. J Biomed Inform 2006, 39:720–736. This article develops a new cognitive neuroscience model of risky decision-making, which incorporates a large body of scientific literature across disciplines. It is both complex and innovative, and has important implications for HIV research.CrossRefPubMed
48.
Charng H, Piliavin JA, Callero PL: Role-identity and reasoned action in the prediction of repeated behavior. Soc Psychol Q 1988, 51:303–317.CrossRef
49.
Hagger M, Anderson M, Kyriak M, Darkings S: Aspects of identity and their influence on intentional behavior: Comparing effects for three health behaviors. Pers Individ Dif 2007, 42:355–367.CrossRef
50.
Pierro A, Mannetti L, Livi S: Self identity and the theory of planned behavior in the prediction of health behavior and leisure activity. Self Identity 2003, 2:47–60.CrossRef
Metadata
Title
Pre-exposure Prophylaxis State of the Science: Empirical Analogies for Research and Implementation
Authors
Sarit A. Golub
Don Operario
Pamina M. Gorbach
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2010
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-010-0057-1

Other articles of this Issue 4/2010

Current HIV/AIDS Reports 4/2010 Go to the issue

ReviewPaper

Readiness: The State of the Science (or the Lack Thereof)

ReviewPaper

Alcohol and HIV Disease Progression: Weighing the Evidence

ReviewPaper

Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use

ReviewPaper

Increasing and Supporting the Participation of Persons of Color Living with HIV/AIDS in AIDS Clinical Trials

ReviewPaper

Drug Treatment as HIV Prevention: Expanding Treatment Options

ReviewPaper

Retention in Care among HIV-Infected Patients in Resource-Limited Settings: Emerging Insights and New Directions
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits